US EditionCIFABOL Questions ‘Insufficient’ Updating of Reference Prices for Domestic Medicinal Products
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.2 Articles
2 Articles
The Chamber of the Bolivian Pharmaceutical Industry (CIFABOL) expresses its concern about what it considers an insufficient and incomplete levelling in the referential prices of medicines of national production, according to the provision issued by the State Agency for Medicines and Health Technologies (Agemed), under the Ministry of Health and Sports. By letter sent to Minister María Renée Castro, CIFABOL announced that the official update only…
The Bolivian pharmaceutical industry demands a "fair and complete" leveling for 344 products, after official provision that only includes 97. The Chamber of the Bolivian Pharmaceutical Industry (CIFABOL) raised a formal protest to the Ministry of Health and Sports for what qualifies as an "incomplete and disadvantageous leveling" in the reference prices of medicines of national production, established by the State Agency for Medicines and Techno…
Coverage Details
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
